Supernus Pharmaceuticals (SUPN) News Today $31.60 -0.07 (-0.22%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Renaissance Technologies LLC Reduces Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Renaissance Technologies LLC trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,598,722 shares oApril 12 at 6:28 AM | marketbeat.comNorges Bank Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Norges Bank acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,551 shares of the specialty pharmaceuticalApril 12 at 4:02 AM | marketbeat.comQ4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals StocksApril 10, 2025 | msn.comCapula Management Ltd Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Capula Management Ltd bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,574 shares of the specialty pharmaceutApril 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 24th. The tradApril 10, 2025 | marketbeat.comTrexquant Investment LP Sells 20,677 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Trexquant Investment LP reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 21.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,275 shares of the specialty pharmaceutical company'sApril 9, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Arrowstreet Capital Limited Partnership grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 79.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 174,916 shares of the specialty pharmaceutical company's stock after acqApril 9, 2025 | marketbeat.comVanguard Group Inc. Has $222.41 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,150,759 shaApril 7, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Schroder Investment Management GroupSchroder Investment Management Group decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 42.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,657 shApril 5, 2025 | marketbeat.comPrudential Financial Inc. Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Prudential Financial Inc. raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,733 shares of the specialty pharmApril 5, 2025 | marketbeat.comSupernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?April 5, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) Raised to "Strong-Buy" at StockNews.comStockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday.April 3, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 34,343 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Pictet Asset Management Holding SA lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 526,252 shares of the specialty pharmApril 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Short Interest Down 17.0% in MarchSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 5,030,000 shares, a decrease of 17.0% from the February 28th total of 6,060,000 shares. Based on an average daily trading volume, of 555,900 shares, the short-interest ratio is currently 9.0 days. Approximately 10.0% of the company's shares are short sold.April 2, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Axiom Investors LLC DEAxiom Investors LLC DE lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 38.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,896 shares of the specialty pharmaceutical company'sApril 2, 2025 | marketbeat.comSei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Sei Investments Co. lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 296,915 shares of the specialty pharmaceutical company's stockMarch 31, 2025 | marketbeat.com41,700 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 41,700 shares of the specialty pharmaceutical compaMarch 30, 2025 | marketbeat.comLoomis Sayles & Co. L P Has $53.05 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Loomis Sayles & Co. L P lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,467,027 shares of the specialMarch 29, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)American Century Companies Inc. increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,140,705 shares of the specialty pharmaceutiMarch 29, 2025 | marketbeat.comUnpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals StocksMarch 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to "Buy" Rating by StockNews.comStockNews.com cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.March 25, 2025 | marketbeat.com11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLCProficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,282 shares of the specialtyMarch 25, 2025 | marketbeat.comRaymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 189,364 shares of the specialty pharmaceutical company's sMarch 24, 2025 | marketbeat.comFox Run Management L.L.C. Makes New $1.30 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Fox Run Management L.L.C. bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 35,900 shares of the specialty pharmaceutical company's stock, valued at apprMarch 23, 2025 | marketbeat.com12,938 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Royce & Associates LPRoyce & Associates LP purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,938 shares of the specialty pharmaceutical company's stock, valuedMarch 23, 2025 | marketbeat.comAtria Investments Inc Invests $288,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Atria Investments Inc bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,978 shares of the specialty pharmaceutical company's stock, valued atMarch 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 40,968 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Charles Schwab Investment Management Inc. lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 753,363 shares of the specialty phaMarch 18, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 201,569 shares of the sMarch 16, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at StockNews.comStockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday.March 16, 2025 | marketbeat.comQ4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals StocksMarch 14, 2025 | msn.comGreat Lakes Advisors LLC Acquires Shares of 169,557 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Great Lakes Advisors LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 169,557 shares of the specMarch 14, 2025 | marketbeat.comPromising Growth Prospects for Supernus Pharmaceuticals: Buy Rating Driven by Qelbree and Onapgo Market OpportunitiesMarch 13, 2025 | tipranks.comBank of New York Mellon Corp Boosts Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Bank of New York Mellon Corp increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 399,584 shares of the specialty pharmaceutical company's stock aftMarch 13, 2025 | marketbeat.comVictory Capital Management Inc. Sells 28,550 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Victory Capital Management Inc. trimmed its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 714,321 shares of the specialty pharMarch 11, 2025 | marketbeat.comProficio Capital Partners LLC Acquires Shares of 11,282 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Proficio Capital Partners LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,282 shares of the specialty pharmaceutical compMarch 11, 2025 | marketbeat.comCandriam S.C.A. Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Candriam S.C.A. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 109,327 shares of the specialty pharmaceutical company's stock after selling 32March 9, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday.March 8, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To AnalystsMarch 6, 2025 | insidermonkey.com10 Cash-Rich Small Cap Stocks To Invest In According To AnalystsMarch 6, 2025 | insidermonkey.comPiper Sandler Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)March 6, 2025 | markets.businessinsider.comSupernus to Participate in Two Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comIs Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?March 2, 2025 | msn.comIs Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?March 2, 2025 | insidermonkey.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc.Principal Financial Group Inc. grew its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 296,732 shares of the specialty pharmaceutical company's stock after acquMarch 1, 2025 | marketbeat.comSupernus Pharmaceuticals Enters Oversold Territory (SUPN)March 1, 2025 | nasdaq.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Down 5.3% - Here's What HappenedSupernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.3% - What's Next?February 27, 2025 | marketbeat.comSupernus to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comSupernus Pharmaceuticals (SUPN) Receives a Hold from Cantor FitzgeraldFebruary 26, 2025 | markets.businessinsider.comSupernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPSSupernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.15. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%.February 26, 2025 | marketbeat.comSupernus Pharmaceuticals Q4 revenue beats, EPS misses estimatesFebruary 26, 2025 | za.investing.com Remove Ads Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Media Mentions By Week SUPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.830.86▲Average Medical News Sentiment SUPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼85▲SUPN Articles Average Week Remove Ads Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JAZZ News PRGO News PCRX News OMER News NKTR News ASMB News CPIX News LLY News JNJ News ABBV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SUPN Stock Free SUPN Stock Alerts